Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danielle Petit

Dermatology Liberty Township, OH Medical Doctor

NPI 1841532348 CMS profile 1397713

6770 Cincinnati Dayton Rd Ste 200, Liberty Township, OH 45044

Open in the dashboard

General payments

$1,113

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Petit of Liberty Township, OH is reported in the CMS Open Payments database as having received $1,113 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $860 44
2023 General $16 1
2021 General $12 1
2020 General $89 2
2019 General $137 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Petit
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Danielle Petit were reported at $860. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Danielle Petit Dermatology median Middle half National median
2019 $137 $454 $129–$1,240 $163
2020 $89 $235 $81–$756 $114
2021 $12 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $16 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $860 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $545 30 payments
  2. UCB, Inc. $95 4 payments
  3. Regeneron Healthcare Solutions, Inc. $91 4 payments
  4. Janssen Biotech, Inc. $88 2 payments
  5. Novartis Pharmaceuticals Corporation $70 3 payments
  6. Lilly USA, LLC $56 3 payments
  7. Pfizer Inc. $30 2 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $28 2 payments
  9. Verrica Pharmaceuticals Inc. $24 1 payment
  10. LEO Pharma Inc. $24 1 payment
  11. Other $62 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,041 55 payments
  2. Education $72 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $254 14 payments
  2. SKYRIZI Immunology $219 12 payments
  3. Bimzelx $95 4 payments
  4. TREMFYA $88 2 payments
  5. SKYRIZI Immunology $72 4 payments
  6. COSENTYX $70 3 payments
  7. TALTZ $42 2 payments
  8. EBGLYSS $39 2 payments
  9. DUPIXENT Inflammation And Immunology $34 2 payments
  10. DUPIXENT Immunology And Inflammation $32 1 payment
  11. Other $311 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

469

Median for Dermatology: 534

Drug cost

$70,998

Median for Dermatology: $67,151

Branded share of claims

5.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $57,428
Clobetasol Propionate Generic 69 $2,978
Ammonium Lactate Generic 19 $2,892
Ketoconazole Generic 98 $1,367
Fluorouracil Generic 18 $1,170
Metronidazole Generic 26 $1,155
Tretinoin Generic 20 $720
Doxycycline Hyclate Generic 23 $583
Desonide Generic 12 $545
Fluocinonide Generic 15 $480

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$73,673

Medicare's payments for the services billed

Medicare patients

450

Average age 73

Services billed

2,094

273 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 42%
Ischemic heart disease 28%
Diabetes 24%
Chronic kidney disease 19%
Osteoporosis 17%
Atrial fibrillation 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record